236 related articles for article (PubMed ID: 23083857)
1. Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases.
Lee CT; Barocas D; Globe DR; Oefelein MG; Colayco DC; Bruno A; O'Day K; Bramley T
J Urol; 2012 Dec; 188(6):2114-9. PubMed ID: 23083857
[TBL] [Abstract][Full Text] [Related]
2. Commentary on "economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases." Lee CT, Barocas D, Globe DR, Oefelein MG, Colayco DC, Bruno A, O׳Day K, Bramley T, Department of Urology, University of Michigan, Ann Arbor, MI.: J Urol 2012;188(6):2114-9. [Epub 2012 Oct 18]. doi: 10.1016/j.juro.2012.08.005.
Hollenbeck BK
Urol Oncol; 2014 Oct; 32(7):1089. PubMed ID: 25443143
[TBL] [Abstract][Full Text] [Related]
3. Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system.
Feifer A; Xie X; Brophy JM; Segal R; Kassouf W
Urology; 2010 Sep; 76(3):652-6. PubMed ID: 20394970
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy.
Seo HK; Cho KS; Chung J; Joung JY; Park WS; Chung MK; Lee KH
Urology; 2010 Aug; 76(2):512.e1-7. PubMed ID: 20579709
[TBL] [Abstract][Full Text] [Related]
5. Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor.
Maeda T; Kikuchi E; Matsumoto K; Miyajima A; Oya M
J Urol; 2011 Mar; 185(3):802-6. PubMed ID: 21239010
[TBL] [Abstract][Full Text] [Related]
6. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
7. National practice patterns for immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer.
Cookson MS; Chang SS; Oefelein MG; Gallagher JR; Schwartz B; Heap K
J Urol; 2012 May; 187(5):1571-6. PubMed ID: 22425105
[TBL] [Abstract][Full Text] [Related]
8. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer.
Arends TJ; van der Heijden AG; Witjes JA
J Urol; 2014 Sep; 192(3):708-13. PubMed ID: 24704017
[TBL] [Abstract][Full Text] [Related]
9. Practice based collaboration to improve the use of immediate intravesical therapy after resection of nonmuscle invasive bladder cancer.
Barocas DA; Liu A; Burks FN; Suh RS; Schuster TG; Bradford T; Moylan DA; Knapp PM; Murtagh DS; Morris D; Dunn RL; Montie JE; Miller DC
J Urol; 2013 Dec; 190(6):2011-6. PubMed ID: 23792129
[TBL] [Abstract][Full Text] [Related]
10. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
11. Bladder cancer in Spain 2011: population based study.
Miñana B; Cózar JM; Palou J; Unda Urzaiz M; Medina-Lopez RA; Subirá Ríos J; de la Rosa-Kehrmann F; Chantada-Abal V; Lozano F; Ribal MJ; Rodríguez Fernández E; Castiñeiras Fernández J; Concepción Masip T; Requena-Tapia MJ; Moreno-Sierra J; Hevia M; Gómez Rodríguez A; Martínez-Ballesteros C; Ramos M; Amón Sesmero JH; Pizá Reus P; Bohorquez Barrientos A; Rioja Sanz C; Gomez-Pascual JA; Hidalgo Zabala E; Parra Escobar JL; Serrano O
J Urol; 2014 Feb; 191(2):323-8. PubMed ID: 23994371
[TBL] [Abstract][Full Text] [Related]
12. Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study.
Geijsen ED; de Reijke TM; Koning CC; Zum Vörde Sive Vörding PJ; de la Rosette JJ; Rasch CR; van Os RM; Crezee J
J Urol; 2015 Nov; 194(5):1202-8. PubMed ID: 26143111
[TBL] [Abstract][Full Text] [Related]
13. Perioperative instillation therapy in superficial bladder cancer: is it effective regarding outcome and costs?
Engel RP; Witjes JA
Curr Opin Urol; 2009 Sep; 19(5):511-5. PubMed ID: 19553821
[TBL] [Abstract][Full Text] [Related]
14. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
[TBL] [Abstract][Full Text] [Related]
15. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
Nativ O; Witjes JA; Hendricksen K; Cohen M; Kedar D; Sidi A; Colombo R; Leibovitch I
J Urol; 2009 Oct; 182(4):1313-7. PubMed ID: 19683278
[TBL] [Abstract][Full Text] [Related]
16. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection.
Shapiro O; Jones K; Wang C; Landas S; Haas GP
Can J Urol; 2006 Dec; 13(6):3317-20. PubMed ID: 17187694
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup.
Solsona E; Iborra I; Ricós JV; Monrós JL; Casanova J; Dumont R
J Urol; 1999 Apr; 161(4):1120-3. PubMed ID: 10081851
[TBL] [Abstract][Full Text] [Related]
18. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.
Madeb R; Golijanin D; Noyes K; Fisher S; Stephenson JJ; Long SR; Knopf J; Lyman GH; Messing EM
Cancer; 2009 Jun; 115(12):2660-70. PubMed ID: 19455607
[TBL] [Abstract][Full Text] [Related]
19. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A
J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
[TBL] [Abstract][Full Text] [Related]
20. A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer.
Chen CH; Yang HJ; Shun CT; Huang CY; Huang KH; Yu HJ; Pu YS
Urol Oncol; 2012; 30(4):421-7. PubMed ID: 20870427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
